With 100 online attendees, 180 in-person participants, 15 posters, 16 technologies, and 45 speakers, the 2023 Technology Showcase offered a whirlwind look into biotechnology innovation happening at the Frederick National Laboratory for Cancer Research and National Cancer Institute.
After three years of COVID-19, science has learned much about the disease and the virus that causes it, SARS-CoV-2. But in the bigger biological and clinical picture, there are still many unanswered questions, says Ligia Pinto, Ph.D. That’s what keeps her group, the Vaccine, Immunity, and Cancer Directorate at Frederick National Laboratory, working hard to hunt down answers. Now, they and collaborators have filled in another gap in that bigger picture.
Three NCI Frederick branch chiefs have joined the ranks of three esteemed societies within the last year. While they’re grateful for the honor, they’re trying to share the limelight. The three say the elections serve to applaud their teams’ contributions, acknowledge the importance of investing in other scientists, and underscore that good science happens when many minds come together.
The National Cancer Institute and Frederick National Laboratory for Cancer Research will host the Technology Showcase on Wednesday, September 6, at the FNL’s Advanced Technology Research Facility in Frederick, Md. The seventh annual event highlights NCI and FNL inventions and capabilities available to the external healthcare and biotech communities and offers the opportunity for networking with others in the biomedical research field.
The next Biotech Connector will explore advances in protein production happening in the Frederick, Md., area with talks from three experts working in the field. It is set for 8:00 a.m. on Thursday, August 31, at the Frederick National Laboratory’s Advanced Technology Research Facility in Frederick.
Lyme disease is the most common tick-borne disease in Maryland, spread by bacteria found in the bite of black-legged ticks, also known as deer ticks. Though it’s common, the disease can be difficult to diagnose, sometimes resulting in debilitating symptoms that may have been prevented with proper, timely diagnosis and a simple course of antibiotics.
NCI-MATCH aimed to determine whether certain cancer therapies could be used more broadly. If a medicine is effective against one type of cancer with a specific mutation, the trial asked, could it treat other cancers with the same mutation? After the eight-year trial, scientists say an answer is coming into view
Warm, sunny weather in summer and fall is perfect for outdoor celebrations. Independence Day, Labor Day, family reunions, parades, cookouts, birthday parties—these are all occasions for which folks gather together to enjoy each other’s company, eat great food, and often top off the event with fireworks.
Few things say “summer” like splashing around in water, leaping off a diving board, and soaking up the sun. We’ve all heard the tried-and-true advice for swimming: don’t run near water, don’t swim after eating, don’t do horseplay. But there are some lesser-known ways to reduce your chances of having an accident.
Early in the COVID-19 pandemic, before vaccines were available and while SARS-CoV-2 was wreaking havoc worldwide, Barry O’Keefe, Ph.D., and longtime collaborators in Brazil and Spain pooled their knowledge and resources to study cyanovirin-N (CV-N), a protein from cyanobacteria, photosynthetic bacteria commonly known as blue-green algae. O’Keefe had a hunch it could be developed to fight the spread of SARS-CoV-2.
